Compare iShares MBS ETF (MBB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MBS ETF trades at $89.7 (market cap $35.45B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.2× iShares MBS ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MBB | REGN | |
|---|---|---|
Market Cap | $35.45B | $76.40B |
Volume | 4,982,386 | 626,381 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $852.03 |
52-Week Low | $89.09 | $557.73 |
Typical Hold Time | 96 Days | 107 Days |
Enterprise Value | — | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.22, down 0.16% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The ETF faces headwinds from rising intermediate-term rates and inflation, as noted in recent analysis, while short interest has surged significantly. Recent corporate actions include scheduled dividend payments, but key financial ratios are not available in the provided data.
The outlook for MBB is cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. Investment opportunities exist for income-focused investors attracted to its dividend yield, but risks include further rate hikes and prepayment volatility. Investors should weigh the ETF's role in a diversified fixed income portfolio against potential duration-related losses.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
